C-UTS7targeted protein degradation, TRIM21 E3 ligase, aggregate-selective degraders
0-100 chain-logic scale · 15 dimensions · scored on public evidence
No company beliefs, mission statement, or longevity-related theories are visible in this Wayback snapshot; the captured page only shows a verification/loading interstitial ('Please wait while your request is being verified'), so no substantive company position can be extracted from the provided text.
SourceTrimtech Therapeutics states that toxic, disease-causing protein aggregates are a key driver of certain CNS and inflammatory disorders and that these conditions can be treated through selective targeted degradation of those proteins. The company says it is building a differentiated portfolio of potent, highly specific degraders, called TRIMTACs and TRIMGLUEs, to remove toxic proteins as a transformative therapeutic approach for otherwise intractable diseases.
Source